

10-19-05

IPW

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number: **26619**

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Reg. No.	Name	Reg. No.

As attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent application assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: **26619**

OR

<input type="checkbox"/> Firm/Individual			
Address			
City	State	Zip	
Country			
Telephone	Email		


Assignee Name and Address: Deltagen, Inc.
1031 Bing Street
San Carlos, CA 94070

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee.

Signature		Date: September 13, 2005
Name	Robert J. Driscoll	Telephone: (650) 569-5168
Title	Vice President, Intellectual Property and Legal Affairs	



STATEMENT UNDER 37 CFR 3.73(b)

Applicant: Guenther, Catherine

Docket No.: R126/75658.241

Application No.: 09/883,093

Entitled: Transgenic Mice Containing Nuclear Hormone Receptor Gene Disruptions

Deltagen, Inc., a corporation states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment of the inventor(s) of the patent application identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012271, Frame 0551, or for which a copy thereof is attached.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned is authorized to act on behalf of the assignee.


Respectfully submitted,

Date

10-17-05

26619

PATENT TRADEMARK OFFICE



John E. Burke, Reg. No. 35,836
Greenberg Traurig LLP
1200 17th Street, Suite 2400
Denver, CO 80202
(303) 685-7411
(720) 904-6111 (fax)